BOSTON,
May 6,
2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE:
DNA), which is building the leading platform for cell programming
and biosecurity, today announced its participation in the 27th
American Society of Gene & Cell Therapy (ASGCT) Annual Meeting,
May 7-11, in Baltimore, MD. Ginkgo will present three
posters in cell therapy and give one oral presentation in mRNA
therapeutics. These presentations demonstrate the power of Ginkgo's
platform to drive innovation in the discovery and development of
genetic medicines.
Two cell therapy posters present results which
extend the screening of pooled chimeric antigen receptor (CAR)
libraries to in vivo mouse models and to NK cells. A third
poster details how automated gene knock-in in induced pluripotent
stem cells can enable high throughput screening workflows. The oral
presentation will discuss the use of machine learning in the
discovery of novel mRNA regulatory elements for increased stability
and protein expression.
Over the past year, Ginkgo has significantly
expanded its genetic medicines services (Gene Therapy, Cell
Therapy, and RNA Therapeutics), which empower customers with
Ginkgo's capabilities for AI/ML-enabled massively parallel testing
of genetic designs to leverage vast biological diversity to improve
products.
In February, Ginkgo announced its acquisition of
Patch Biosciences to further expand its suite of genetic medicine
capabilities available to its customers. Ginkgo plans to
incorporate Patch Bio's machine learning models and downstream
assays into its existing platform, making new capabilities in
synthetic promoter and untranslated region (UTR) engineering
available to partners. The addition of Patch Bio's assets opens up
additional commercial opportunities in gene therapy, cell therapy,
and RNA therapeutics and has the potential to accelerate progress
on current programs.
Shawdee Eshghi,
Senior Director, Mammalian Engineering, Ginkgo
Bioworks: "Our ASGCT presentations this year represent
advances in large library screening in vivo and in
vitro, the use of automation for high throughput genome
engineering in iPSCs, and the application of machine learning to
the design of improved gene therapies. We're excited to demonstrate
the value our services can bring to cell and gene therapy
developers."
Information on the poster presentations and oral
presentation are listed below, and the full abstracts are available
on the ASGCT meeting website.
Poster presentations:
- Pooled Screening for CAR Signaling Optimizes Function
in NK Cells
Abstract number: 821
Session: Wednesday Poster Session
Presenter: Khloe Gordon Wei
Date and Time: Wednesday, May 8, 2024
12:00 PM ET
- In Vivo Pooled Screening Platform for the Discovery of
Optimized Chimeric Antigen Receptor (CAR) Design in T
cells
Abstract number: 826
Session: Wednesday Poster Session
Presenter: Joshua Mace
Date and Time: Wednesday, May 8, 2024
12:00 PM ET
- From Promoter to Transgene Efficiency: Insights from
Promoter Screening in Induced Pluripotent Stem
Cells
Abstract number: 1672
Session: Friday Poster Session
Presenter: Kiavash Kiaee
Date and Time: Friday, May 10, 2024
12:00 PM ET
Oral presentation:
- Machine-Designed Synthetic 3' UTRs Significantly
Increase mRNA Stability
Abstract Number: 410
Session: Vector Product Engineering, Development, and Manufacturing
(excluding AAV)
Presenter: Elise Flynn
Date and Time: Saturday, May 11, 2024
10:45 AM ET
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal
platform for cell programming, providing flexible, end-to-end
services that solve challenges for organizations across diverse
markets, from food and agriculture to pharmaceuticals to industrial
and specialty chemicals. Ginkgo Biosecurity is building and
deploying the next-generation infrastructure and technologies that
global leaders need to predict, detect, and respond to a wide
variety of biological threats. For more information, visit
ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or
follow us on social media channels such as X (@Ginkgo and
@Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads
(@GinkgoBioworks), or LinkedIn.
GINKGO BIOWORKS INVESTOR
CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
Forward-Looking Statements of Ginkgo
Bioworks
This press release contains certain
forward-looking statements within the meaning of the federal
securities laws, including statements regarding Ginkgo's
capabilities in gene therapy, cell therapy, and RNA therapeutics,
the benefits of Ginkgo's acquisition of Patch Bio, and the
potential success of Ginkgo's cell programming platform. These
forward-looking statements generally are identified by the words
"believe," "can," "project," "potential," "expect," "anticipate,"
"estimate," "intend," "strategy," "future," "opportunity," "plan,"
"may," "should," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) volatility in the price of Ginkgo's securities due
to a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo operates and plans to
operate, variations in performance across competitors, and changes
in laws and regulations affecting Ginkgo's business, (ii) the
ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional business
opportunities, (iii) the risk of downturns in demand for products
using synthetic biology, (iv) the uncertainty regarding the demand
for passive monitoring programs and biosecurity services, (v)
changes to the biosecurity industry, including due to advancements
in technology, emerging competition and evolution in industry
demands, standards and regulations, (vi) the outcome of any pending
or potential legal proceedings against Ginkgo, (vii) our ability to
realize the expected benefits from and the success of our Foundry
platform programs, (viii) our ability to successfully develop
engineered cells, bioprocesses, data packages or other
deliverables, and (ix) the product development or commercialization
success of our customers. The foregoing list of factors is not
exhaustive. You should carefully consider the foregoing factors and
the other risks and uncertainties described in the "Risk Factors"
section of Ginkgo's annual report on Form 10-K filed with the U.S.
Securities and Exchange Commission (the "SEC") on February 29, 2024 and other documents filed by
Ginkgo from time to time with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Ginkgo assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance
that it will achieve its expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-presentations-at-the-upcoming-american-society-of-gene--cell-therapy-asgct-annual-meeting-302136381.html
SOURCE Ginkgo Bioworks